The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM | CAR-T updates at COSTEM 2021
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, gives an overview of key highlights in the field of chimeric antigen receptor T-cell (CAR-T) therapy being discussed at the 2021 COSTEM meeting. Prof. Nagler discusses the approval of four CAR-T products for various forms of non-Hodgkin lymphoma, and the approval of one CAR-T product for multiple myeloma with another one pending. Prof. Nagler also describes how CAR-T may replace allogeneic transplantation and autologous transplantation and comments on the role of other immunotherapies. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
